{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:23:15Z","timestamp":1779193395838,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,8,3]],"date-time":"2009-08-03T00:00:00Z","timestamp":1249257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Rationale<\/jats:title><jats:p>Methadone and buprenorphine are among the most widely employed pharmacological treatments currently available for opioid addiction. Cognitive effects of buprenorphine in abstinent heroin abusers are nevertheless far from being understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Neuropsychological performance of 18 buprenorphine\u2010maintained patients (BMP) was evaluated relative to that of 32 currently abstinent heroin abusers on naltrexone hydrochloride therapy (FHAN), and 34 non\u2010drug dependent controls. The three groups were demographically balanced. Clinical groups reported histories of similar patterns of drug use and had increased periods of abstinence from any illicit substance use including heroin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The BMP group performed poorer than controls on the RAVLT (encoding and delayed recall of verbal information), CTT (conceptual flexibility, executive functions) and the RBANS figure copy (visual perception) and delayed recall of visual information. There were no significant differences in any of the cognitive measures between the BMP and FHAN groups or between the FHAN group and controls. Furthermore, the non\u2010differing percentage of abnormal cases between the two patient groups led us to infer that treatment with either BPM or FHAN is not accompanied by qualitative differences in the cognitive profiles of these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Overall, results suggest that treatment with naltrexone in abstinent heroin abusers may result in less impairment of cognitive functions compared to treatment with buprenorphine. These findings are relevant for improved prognosis and treatment strategies in opioid dependence. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1050","type":"journal-article","created":{"date-parts":[[2009,8,3]],"date-time":"2009-08-03T09:07:26Z","timestamp":1249290446000},"page":"524-531","source":"Crossref","is-referenced-by-count":35,"title":["Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy"],"prefix":"10.1002","volume":"24","author":[{"given":"Lambros","family":"Messinis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Epameinondas","family":"Lyros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Andrian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Katsakiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Panagis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Papathanasopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,3]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_1_3_1","unstructured":"ArgirokastritouE SamandaT MessinisL.2005. Preliminary Normative Data for the Symbol Digit Modalities Test (SDMT) in Greece.Presented at the 10th Panhellenic Congress of Psychology Ioannina 1\u20134 December."},{"key":"e_1_2_1_4_1","volume-title":"Beck Depression Inventory \u2010Fast Screen for Medical Patients: Manual","author":"Beck AT","year":"2000"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060403"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000628"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(02)00012-1"},{"key":"e_1_2_1_8_1","unstructured":"European Monitoring Centre for Drugs Drug Addiction Annual Report 2006.The State of the Drugs Problem in Europe. Luxembourg: Office for Official Publications of the European Communities."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00067-X"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300251"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.14.2.157"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-007-9041-y"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1355617704102014"},{"key":"e_1_2_1_14_1","unstructured":"MessinisL GourzoulidouE LyrosE PapathanasopoulosP.2008. Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary normative data for clinical and research use in Greece.Presented at the 22nd Panhellenic Neurology Congress Chania 1\u20134 May."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acn.2007.06.005"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000201279.83203.c6"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acn.2007.06.002"},{"key":"e_1_2_1_18_1","unstructured":"MessinisL TsakonaI PapathanasopoulosP.2009. Wechsler Abbreviated Scale of Intelligence (WASI) (Greek adaptation).Unpublished Data Neuropsychological laboratory Department of Neurology University of Patras Medical School Greece."},{"key":"e_1_2_1_19_1","unstructured":"MessinisL PapathanasopoulosP MalefakiS.(in press) Color Trails Test: Preliminary Normative data and Discriminant validity for the adult Greek population. Scientific Proceedings \u201cEleutherna\u201d Department of Psychology University of Crete"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.10.008"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001333.pub2"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.11.008"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.02.006"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1515\/REVNEURO.2001.12.2.141"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-7-5"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2006.10.005"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000178417.60426.60"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.13.4.527"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31818a6d38"},{"key":"e_1_2_1_30_1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0022-3565(25)24449-4","article-title":"Buprenorphine effects in methadone\u2010maintained volunteers: effects at two hours after methadone","volume":"272","author":"Strain EC","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(01)00207-6"},{"key":"e_1_2_1_32_1","unstructured":"TsolakiM TsantaliE LekkasS KiosseoglouG KazisA.2003. Can the Boston Naming Test be used as clinical tool for differential diagnosis in Dementia?Presented at the 41st Annual Meeting of Academy of Aphasia Vienna 19\u201321 October."},{"key":"e_1_2_1_33_1","unstructured":"United Nations Office on Drugs and Crime World Drug Report.2004.Volume1 United Nations Publication No. E.04.X1.16 Vienna Austria"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.11.006"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1355617706060486"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001955"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2003.10.017"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00110-X"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1050","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:13:14Z","timestamp":1739290394000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,3]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1002\/hup.1050"],"URL":"https:\/\/doi.org\/10.1002\/hup.1050","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,3]]}}}